Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention

Pharmacogenetics and Genomics

Volumn 23, Issue 10, 2013, Pages 558-562

  Park, Mahn Won ^a   Her, Sung Ho ^a   Kim, Ho Sook ^i,j   Choi, Yun Seok ^b   Park, Chul Soo ^b   Koh, Yoon Seok ^c   Park, Hun Jun ^d   Kim, Pum Joon ^d   Kim, Chan Joon ^a   Jeon, Doo Soo ^e   Shin, Dong Il ^e   Seo, Suk Min ^e   Yoo, Ki Dong ^f   Kim, Dong Bin ^g   Kim, Hee Yeol ^h   Lee, Jong Min ^c   Chung, Wook Sung ^d   Seung, Ki Bae ^d   Shin, Jae Gook ^i,j   Chang, Kiyuk ^d  

^a Daejeon St Mary's Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Uijeongbu St Mary's Hospital   (South Korea)

^d St Mary's Hospital   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Department of Cardiology   (South Korea)

^g St Paul's Hospital   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ Dong A University   (South Korea)

^j Inje University College of Medicine   (South Korea)

more..

Author keywords

bleeding; clopidogrel; CYP2C19; polymorphisms; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; ALLELE; ARTICLE; ASIAN; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; DEATH; DRUG ELUTING STENT; GENE FREQUENCY; GENETIC POLYMORPHISM; HEART INFARCTION; HOMOZYGOTE; HUMAN; KOREA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; STENT THROMBOSIS; DRUG ADMINISTRATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENETICS; GENOTYPE; HEART MUSCLE ISCHEMIA; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; GENETIC VARIATION; HEMORRHAGE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA;

ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; DRUG ADMINISTRATION SCHEDULE; GENETIC LINKAGE; GENETIC VARIATION; GENOTYPE; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TICLOPIDINE; CYTOCHROME P-450 CYP2C19;

EID: 84885053151     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328364eb92     Document Type: Article

References (10)

1. Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, et al. Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 2011; 22:399-407.
2. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Mé neveau N. The French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-375.
3. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19. 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121:512-518.
4. Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19.*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 2008; 65:437-439.
5. Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schoümig A, et al. Protective effect of the CYP2C19.*17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010; 160:506-512.
6. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the leading Academic Research Consortium. Circulation 2011; 123:2736-2747.
7. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115:2344-2351.
8. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19.*17. Br J Clin Pharmacol 2010; 69:222-230.
9. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease results of the CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drugeluting stenT implantation) trial. J Am Coll Cardiol 2011; 57:280-289.
10. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) Trial. J Am Coll Cardiol 2011; 57:1264-1270.